PANTAFLIX AG

  • WKN: A12UPJ
  • ISIN: DE000A12UPJ7
  • Land: Deutschland

Nachricht vom 24.11.2021 | 18:19

PANTAFLIX AG resolves on capital increase against cash contributions from authorized capital with private placement

PANTAFLIX AG / Key word(s): Corporate Action
PANTAFLIX AG resolves on capital increase against cash contributions from authorized capital with private placement

24-Nov-2021 / 18:19 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


PANTAFLIX AG resolves on capital increase against cash contributions from authorized capital with private placement

Munich, November 24, 2021. The Management Board of PANTAFLIX AG, Munich, (ISIN: DE000A12UPJ7) today resolved, with the approval of the Supervisory Board, to increase the Company's issued share capital from EUR 18,601,390 by issuing 1,860,139 new no-par value bearer shares (this corresponds to 10% of the current issued share capital) at an issue amount of EUR 1.19 per new share, i.e. at a total issue amount of EUR 2,213,565.41 against cash contributions partially utilizing the existing authorized capital and excluding the existing shareholders' subscription rights.

The capital increase is completely placed. The new shares will be included without a prospectus in the existing listing in the Scale Segment of the Frankfurt Stock Exchange. The capital increase should strengthen the balance sheet and finance the further growth of PANTAFLIX AG.

The transaction was accompanied by Hauck & Aufhäuser.

November 24, 2021
The Management Board

Investor Relations
CROSS ALLIANCE communication GmbH
Susan Hoffmeister
Tel.: +49 (0)89 1250903-30
E-Mail: sh@crossalliance.de
Website: www.crossalliance.de


24-Nov-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021